Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Statistical Process Control Charts for Monitoring Next-Generation Sequencing and Bioinformatics Turnaround in Precision Medicine Initiatives.
Jain SR, Sim W, Ng CH, Chin YH, Lim WH, Syn NL, Kamal NHBA, Gupta M, Heong V, Lee XW, Sapari NS, Koh XQ, Isa ZFA, Ho L, O'Hara C, Ulagapan A, Gu SY, Shroff K, Weng RC, Lim JSY, Lim D, Pang B, Ng LK, Wong A, Soo RA, Yong WP, Chee CE, Lee SC, Goh BC, Soong R, Tan DSP. Jain SR, et al. Among authors: wong a. Front Oncol. 2021 Sep 24;11:736265. doi: 10.3389/fonc.2021.736265. eCollection 2021. Front Oncol. 2021. PMID: 34631570 Free PMC article.
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors.
Choo JRE, Jan YH, Ow SGW, Wong A, Lee MX, Ngoi N, Yadav K, Lim JSJ, Lim SE, Chan CW, Hartman M, Tang SW, Goh BC, Tan HL, Chong WQ, Yvonne ALE, Chan GHJ, Chen SJ, Tan KT, Lee SC. Choo JRE, et al. Among authors: wong a. Target Oncol. 2022 May;17(3):355-368. doi: 10.1007/s11523-022-00886-x. Epub 2022 Jun 14. Target Oncol. 2022. PMID: 35699834 Free PMC article.
Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia.
Low JL, Lim E, Bharwani L, Wong A, Wong K, Ow S, Lim SE, Lee M, Choo J, Lim J, Chan G, Walsh RJ, Muthu V, Ngoi N, Chong W, Tan SH, Lee SC. Low JL, et al. Among authors: wong a, wong k. Ther Adv Med Oncol. 2022 Dec 18;14:17588359221139678. doi: 10.1177/17588359221139678. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36570409 Free PMC article.
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer.
Yadav K, Lim J, Choo J, Ow SGW, Wong A, Lee M, Chan CW, Hartman M, Lim SE, Ngoi N, Tang SW, Ang Y, Chan G, Chong WQ, Tan HL, Tan SH, Goh BC, Lee SC. Yadav K, et al. Among authors: wong a. Breast Cancer Res Treat. 2022 Feb;192(1):131-142. doi: 10.1007/s10549-021-06470-7. Epub 2021 Dec 20. Breast Cancer Res Treat. 2022. PMID: 34928481 Free PMC article. Clinical Trial.
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.
Lim JSJ, Wong ALA, Ow SGW, Ngoi NYL, Chan GHJ, Ang YLE, Chong WQ, Lim SE, Lim YW, Lee M, Choo JRE, Tan HL, Yong WP, Soo RA, Tan DSP, Chee CE, Sundar R, Yadav K, Jain S, Wang L, Tai BC, Goh BC, Lee SC. Lim JSJ, et al. Among authors: wong ala. Clin Cancer Res. 2022 Jun 1;28(11):2248-2256. doi: 10.1158/1078-0432.CCR-21-4179. Clin Cancer Res. 2022. PMID: 35363275 Clinical Trial.
7,334 results